T1	Participants 57 99	patients with active rheumatoid arthritis:
T2	Participants 353 649	Patients ages ≥18 years with active RA with an inadequate response to ≥1 tumor necrosis factor inhibitor (TNFi) and receiving stable background methotrexate were randomized 2:2:1:1 to tofacitinib 5 mg or 10 mg twice daily, or placebo advanced to tofacitinib 5 mg or 10 mg twice daily at month
T3	Participants 1845 1924	treatment in patients with active RA and a previous inadequate response to TNFi
